Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 15/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015695 | 0.94 | ACE (0.70) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL905736 | 0.92 | ACE (0.77) | ACELMNASMN1; SMN2 | |
| SCHEMBL7324222 | 0.92 | ACE (0.87) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL6417922 | 0.92 | ACE (0.87) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Hydrochloric Acid SCHEMBL6414637 | 0.91 | ACE (0.85) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Hydrochloric Acid SCHEMBL7333419 | 0.91 | ACE (0.85) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL16364868 | 0.91 | ACE (0.85) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL14001337 | 0.90 | ACE (0.87) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL10802722 | 0.89 | ACE (0.82) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL9863830 | 0.89 | ACE (0.82) | ACELMNASMN1; SMN2ABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456467-B1 | EPSILON-POLYLYSINE CONJUGATES AND USE THEREOF | MERCK PATENT GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| US-9078929-B2 | ε-Polylysine conjugates and the use thereof | MERCK PATENT GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| EP-2456467-A1 | -POLYLYSINE CONJUGATES AND USE THEREOF | Merck Patent GmbH (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20120122788-A1 | E-POLYLYSINE CONJUGATES AND THE USE THEREOF | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2011009539-A1 | ε-POLYLYSINE CONJUGATES AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-01-27 | — | — | WO | disclosed |
| EP-2277547-A1 | Epsilon-polylysine conjugates and their utilisation | Merck Patent GmbH (DE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2007089745-A2 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R & D HOLDINGS, LLC (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122788-A1 | E-POLYLYSINE CONJUGATES AND THE USE THEREOF | LNPEP, EEA1, DNPEP | ACE 1355/4885LMNA 379/4885SMN1; SMN2 4116/4885 |
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | IL4I1, SLC7A1, GOT1 | ACE 96/4885LMNA 4367/4885SMN1; SMN2 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.